CALR mutations in myeloproliferative neoplasms: Hidden behind the reticulum

American Journal of Hematology

Volumn 89, Issue 5, 2014, Pages 453-456

  Guglielmelli, Paola ^a   Nangalia, Jyoti ^b,c   Green, Anthony R ^b,c   Vannucchi, Alessandro M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; RUXOLITINIB; STAT PROTEIN; THROMBOPOIETIN RECEPTOR;

ACUTE LEUKEMIA; ARTICLE; CALCIUM HOMEOSTASIS; CANCER DIAGNOSIS; CHROMOSOME 19; CHROMOSOME 1P; CHROMOSOME 8; CHRONIC MYELOMONOCYTIC LEUKEMIA; CODON; ENDOPLASMIC RETICULUM; EXON; GAIN OF FUNCTION MUTATION; HETEROZYGOSITY LOSS; HOMOZYGOSITY; HUMAN; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; SIGNAL TRANSDUCTION; SPLICEOSOME; TRANSIENT EXPRESSION;

AMINO ACID SEQUENCE; ANIMALS; CALRETICULIN; HEMATOLOGIC NEOPLASMS; HUMANS; MICE; MOLECULAR SEQUENCE DATA; MYELOPROLIFERATIVE DISORDERS; POINT MUTATION;

EID: 84898417272     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23678     Document Type: Article

References (10)

1. Vainchenker W, Delhommeau F, Constantinescu SN, et al. New mutations and pathogenesis of myeloproliferative neoplasms. Blood 2011;118:1723-1735.
2. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013;369:2391-2405.
3. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369:2379-2390.
4. Lasho TL, Elliott MA, Pardanani A, et al. CALR mutation studies in chronic neutrophilic leukemia. Am J Hematol, 2014 Jan 13. doi: 10.1002/ajh.23665
5. Gold LI, Eggleton P, Sweetwyne MT, et al. Calreticulin: non-endoplasmic reticulum functions in physiology and disease. FASEB J 2010;24:665-683.
6. Caramelo JJ, Parodi AJ. Getting in and out from calnexin/calreticulin cycles. J Biol Chem 2008;283:10221-10225.
7. Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL mutated or triple-negative myelofibrosis: Clinical, cytogenetic and molecular comparisons. Leukemia, 2014 Jan 9. doi: 10.1038/leu.2014.3.
8. Chi J, Nicolaou K, Nicolaidou V, et al. Calreticulin exon 9 frame-shift mutations in patients with thrombocytosis. Leukemia, 2013 Dec 24. doi: 10.1038/leu.2013.382.
9. Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood, 2013 Dec 24.
10. Rotunno G, Mannarelli C, Guglielmelli P, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood, 2013 Dec 26.